Mandy Whitt, MD
Family Medicine · Louisville, KYNPI 1841511698
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $32,069 of the $37,594 with a category attached, or 85.3%. 21 manufacturers reported payments, led by Pfizer at 49.2% of the total. 2025 is the largest year on record at $17,026, more than ten times the $754 reported in 2019. Among family medicine clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 208 payments — averaging $180.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$18K
- AbbVie$18K
- Biohaven Pharmaceuticals, Inc.$239
- Sanofi-aventis U.S. LLC$123
- Axsome Therapeutics, Inc.$118
- Amgen$82
- plus $505 from 15 others
What the payments were for
- Consulting fees$1,5254%
- Speaking & faculty fees$32,06985%
- Travel & lodging$1,0413%
- Food & beverage$2,9598%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 66 | $18,493 |
| AbbVie | 78 | $18,035 |
| Biohaven Pharmaceuticals, Inc. | 18 | $239 |
| Sanofi-aventis U.S. LLC | 2 | $123 |
| Axsome Therapeutics, Inc. | 1 | $118 |
| Amgen | 5 | $82 |
| Novartis | 5 | $64 |
| Boehringer Ingelheim | 5 | $58 |
| Novo Nordisk | 4 | $49 |
| GSK | 4 | $48 |
| Amarin Pharma, Inc. | 3 | $44 |
| Supernus Pharmaceuticals, Inc. | 3 | $43 |
| UCB, Inc. | 2 | $33 |
| Lilly USA, LLC | 2 | $30 |
| Jazz Pharmaceuticals Inc. | 2 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $21 |
| Astellas Pharma US Inc | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,594 in reported general payments places this provider in the 95th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 160 | $132,495 |
| Nurtec OdtRimegepant Sulfate | 81 | $96,843 |
| UbrelvyUbrogepant | 68 | $73,163 |
| Aimovig AutoinjectorErenumab-Aooe | 89 | $70,288 |
| QuliptaAtogepant | 36 | $44,965 |
| Emgality SyringeGalcanezumab-Gnlm | 13 | $21,991 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 11 | $15,074 |
| Zolmitriptan | 18 | $5,116 |
| Sumatriptan Succinate | 73 | $4,449 |
| Memantine Hcl | 58 | $1,500 |
| Acetazolamide | 19 | $1,477 |
| Gabapentin | 91 | $1,326 |
| Oxcarbazepine | 36 | $1,124 |
| Topiramate | 125 | $1,103 |
| Amitriptyline Hcl | 125 | $879 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $18,035 | $118,128104 claims |
| PfizerNurtec Odt | $18,493 | $96,84381 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Louisville
- Christopher RhyneLouisville$933K
- Suraj GathaniLouisville$69K
- Michael PendletonLouisville$29K
- Rajanbhai AminLouisville$26K
- James WrightLouisville$18K
- Rosenberg ReyesLouisville$18K
- Dennis GrayLouisville$14K
- Vincent LangLouisville$12K
- Jaivanti LohanoLouisville$11K
- John RichardLexington$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.